Because CD44+/CD166+ double-positive cells are more tumorigenic than CD44+ single-positive cells in colorectal cancers, CD166 is an attractive marker for the further enrichment of CD44+ CSCs [5]. Here, ALCAM is linked to colorectal cancer.